The pharmacokinetic/pharmacodynamic research tool (PRESTO):: An advanced concept for rational drug development

被引:0
作者
Göller, G
Mück, W
Koss, D
Nörtersheuser, P
Osswald, M
Kovar, A
Zurth, C
Poland, H
机构
[1] Bayer AG, PH PD P Preclin Pharmacokinet, D-42096 Wuppertal, Germany
[2] Asta Med AG, Frankfurt, Germany
[3] Abbott GmbH & Co KG, Wiesbaden, Germany
[4] Boehringer Ingelheim Pharma KG, Biberach, Germany
[5] Merck KGaA, Darmstadt, Germany
[6] Schering AG, D-1000 Berlin, Germany
来源
DRUG INFORMATION JOURNAL | 2002年 / 36卷 / 01期
关键词
pharmacokinetics; pharmacodynamics; data analysis; data repository; data management;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In Germany in 1995 an intercompany expert working group was formed to define a flexible structure for a modern database system, named the Pharmacokinetic/Pharmacodynamic RESearch TOol (PRESTO), which handles pharmacokinetic/pharmacodynamic (PK/PD) results of entire research and development (R&D) projects, thus going beyond the information available in laboratory or clinical data systems generally present in most companies. PRESTO consists of two main modules: a database and an analysis system. The database part of PRESTO is designed for storing and managing PK and PD study data. Associated information such as biochemistry, toxicokinetic, physico-chemistry, and clinical chemistry data can also be handled to aid the interpretation of results, if necessary. The database will be used as a source for all kinds of pharmacokinetic, pharmacodynamic, and biometric evaluations. The extraction of data across studies to prepare meta-analyses is an essential feature of this system. The analysis system part of PRESTO provides uniform graphical interfaces to the database and to commercially available and proprietary data analysis programs (noncompartmental, compartmental PK, effect modeling, population PK/PD) as well as statistical software packages. The database part is then additionally used as a repository of the results from these evaluations. PRESTO is designed to a modular concept and a flexible data model, and offers configuration to site-specific needs. The concept supports fulfillment of Good Clinical Practice/Good Laboratory Practice requirements.
引用
收藏
页码:57 / 66
页数:10
相关论文
共 14 条
  • [1] Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies
    Aarons, L
    Balant, LP
    Mentre, F
    Rowland, M
    Steimer, JL
    Vozeh, S
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) : 251 - 254
  • [2] [Anonymous], 1997, DATA STORES DATA WAR
  • [3] [Anonymous], PHARMACOKINETIC PHAR
  • [4] BINDER R, 1997, COST B1 MED EUROPEAN
  • [5] Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development - The 'Wooden Shoe' paradigm
    Breimer, DD
    Danhof, M
    [J]. CLINICAL PHARMACOKINETICS, 1997, 32 (04) : 259 - 267
  • [6] Gibaldi M, 1982, Drugs and the Pharmaceutical Sciences, V15
  • [7] HEINZEL G, 1993, TOPFIT VERSION 2 0 P
  • [8] International Conference on Harmonization (ICH), 1997, FED REG, V62, P25691
  • [9] Organisation for Economic Cooperation and Development, 1998, SER PRINC GOOD LAB P, V1
  • [10] OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT
    PECK, CC
    BARR, WH
    BENET, LZ
    COLLINS, J
    DESJARDINS, RE
    FURST, DE
    HARTER, JG
    LEVY, G
    LUDDEN, T
    RODMAN, JH
    SANATHANAN, L
    SCHENTAG, JJ
    SHAH, VP
    SHEINER, LB
    SKELLY, JP
    STANSKI, DR
    TEMPLE, RJ
    VISWANATHAN, CT
    WEISSINGER, J
    YACOBI, A
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 465 - 473